The bill has received bipartisan support for removing barriers and accelerating innovation in medical devices, drugs and biologics.
Change is constant, and we continue to evolve.
The comprehensive approach to human factors considers how a product operates alone, interoperability in larger settings, and data management.
Companies recruiting Asian executives need to do double the due diligence than is customary for hiring a Western executive.
The device tax, regulatory scrutiny, and a failure to address unmet clinical needs are among the reasons that the United States will fall behind other major markets.
Johnson & Johnson holds firm that it will continue to accelerate in the innovation department over the next year.
The market value for transcatheter heart valves will exceed $3 billion by 2020, and adoption of next-generation valves will drive significant market growth, provided that positive clinical data continues, according to research and consulting firm GlobalData.
Cardinal CEO George Barrett has said that the company may make more acquisitions in cardiology and endovascular treatment as well as in the trauma and wound care segment.
Uber has taken the struggling, often unloved taxi industry and reinvented it successfully based largely on one premise: Customer is king. In stark contrast, the healthcare industry clearly does not seem to share this mantra.
There are great opportunities for foreign medical device companies in China as the people want better healthcare, the government is increasing access to healthcare, and the market is growing between 15 and 20 percent per year. But access to the marketplace is harder than ever. Why?